EU recommends extended indication for Prevenar
Prevenar is currently approved for active immunization of children from 2 months to 5 years of age against sepsis, meningitis, bacteraemic pneumonia and bacteraemia. Pneumococcal disease is a
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.